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ABSTRACT
Artificial transcription factors (ATFs) and genomic
nucleases based on a DNA binding platform consist-
ing of multiple zinc finger domains are currently be-
ing developed for clinical applications. However, no
genome-wide investigations into their binding speci-
ficity have been performed. We have created six-
finger ATFs to target two different 18 nt regions of
the human SOX2 promoter; each ATF is constructed
such that it contains or lacks a super KRAB do-
main (SKD) that interacts with a complex contain-
ing repressive histone methyltransferases. ChIP-seq
analysis of the effector-free ATFs in MCF7 breast
cancer cells identified thousands of binding sites,
mostly in promoter regions; the addition of an SKD
domain increased the number of binding sites ∼5-
fold, with a majority of the new sites located out-
side of promoters. De novo motif analyses suggest
that the lack of binding specificity is due to sub-
sets of the finger domains being used for genomic
interactions. Although the ATFs display widespread
binding, few genes showed expression differences;
genes repressed by the ATF-SKD have stronger bind-
ing sites and are more enriched for a 12 nt motif.
Interestingly, epigenetic analyses indicate that the
transcriptional repression caused by the ATF-SKD is
not due to changes in active histone modifications.
INTRODUCTION
Dysregulation of normal epigenetic control of DNA methy-
lation and histone modifications at gene promoters and en-
hancers is a hallmark of cancer (1). These regulatory lay-
ers are thought to cooperatively affect nucleosome position-
ing, chromatin structure and subsequent transcription fac-
tor accessibility to the genome (2). Epigenetic drugs tar-
geting DNA methylation (3) and histone modifications (4–
6) have shown promise in restoring some normal epige-
netic features, but because they affect epigenome-regulating
proteins, they are not sequence-specific. Just as modern
small-molecule drugs can minimize classic chemotherapeu-
tic side effects by specifically targeting disease-related pro-
teins (7), artificial transcription factors (ATFs) may soon al-
low precise regulation of disease-related genetic loci. ATFs
are proteins that can be engineered to bind and modulate
the expression of specific genes through epigenetic effec-
tor domains (8,9). Epigenetic activation domains can be
used to demethylate DNA (TET), recruit transcriptional
machinery (VP64) or remove active histone marks (LSD).
Conversely, epigenetic repression domains directly methy-
late DNA (DNMT3a) or recruit repressive histone modi-
fiers (KRAB, SKD) (10). Genomic nucleases targeted by
C2H2 zinc finger (ZNF) DNA binding domains were the
first to be developed (11) and proteins composed of ZNF
DNA binding domains fused to a nuclease have been em-
ployed in clinical trials (NCT00842634, NCT01044654 and
NCT01252641).
Endogenous ZNF proteins, which served as a model for
ATF development, typically bind CG-rich regions, under-
went a drastic expansion in vertebrates, and are the largest
family of transcription factors in humans (12). ZNF DNA
binding domains are comprised of tandem arrays of sev-
eral ZNFs, each specifically interacting with ∼3 nucleotides
(nt) of DNA in an antiparallel orientation. Observations of
endogenous ZNF binding specificities and in vitro refine-
ments lead to the development of the ZNF code for target-
ing DNA sequences of choice (13–18). ATFs typically con-
tain six C2H2 domains intended to target a unique 18 nt
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genomic sequence. The majority of endogenous ZNFs also
contain an amino-terminal effector domain, facilitating in-
teractions with epigenetic modifiers; the most common
ZNF effector domain in humans is the Krüppel-associated
box (KRAB) domain (12). For example, the KRAB do-
main of ZNF274 recruits a complex, comprised of KAP1
and SETDB1, enriching the repressive histone modifica-
tion, H3K9me3, at ZNF274 binding sites (19,20). Simi-
larly, the addition of epigenetic effector domains to artifi-
cial ZNFs, creating ZNF ‘toggle switches’, allows modula-
tion of the local chromatin structure at the intended tar-
get site. Unlike designer genomic nucleases or RNAi-based
approaches, toggle switches can also upregulate silenced
gene expression. For example, KRAB and VP64 effector
domains were able to downregulate or upregulate the EGP-
2 promoter, respectively (21).
A handful of genes have been successfully targeted in
cancer cells and in tumors using ZNF toggle switches. The
silenced tumor suppressor, Maspin, was upregulated us-
ing a VP64 activation domain (22–24) and the TET DNA
demethylase was able to re-activate the ICAM-1 promoter
(25). A ZNF-DNMT3a fusion was used to force methy-
lation and downregulate expression at the promoters of
the Maspin gene and the oncogene SOX2 (26). Stolzen-
burg et al. also targeted the SOX2 promoter employing
a super KRAB domain (SKD) to recruit repressive his-
tone complexes (27). Effects from toggle switches alone
have been fairly modest and no pattern has emerged to
predict the efficacy of repression or activation. However,
treatment of cells with broadly acting epigenetic drugs and
toggle switches can have synergistic effects on target gene
regulation (28). Recent studies of Cas9-based ATF toggle
switches suggest that simultaneous epigenetic targeting of
several neighboring sites may also have synergistic effects
on gene regulation (29). This synergism suggests off-target
effects of a single ATF may be minimal, but using mul-
tiple ATFs clearly requires monitoring genome-wide ATF
binding patterns in vivo. Recent ChIP-seq studies of Tran-
scription Activator-Like Effector (TALE)-based (30) and
Cas9-based (31) ATFs have been informative, but to date,
no genome-wide binding analysis of a ZNF-based ATF has
been reported.
In this study, we examine the genome-wide binding pat-
terns of two previously reported ZNF effectors, 598-SKD
and 552-SKD, which target the SOX2 promoter (26,27). As
598-SKD was more effective in downregulating SOX2 ex-
pression (27), we also profiled effects of this ATF on his-
tone modifications and genome-wide expression. We found
that ZNF-based ATFs bind very broadly, each one binding
to thousands of promoters. However, the activity of only
∼10% of bound promoters was significantly altered by 598-
SKD and changes in histone marks do not correlate with
expression changes. Our results demonstrate a large discon-




ATF plasmids were designed and stably integrated into
MCF7 cells as described in (27). Stable lines were
grown at 30–80% confluency in Dulbecco’s Modified
Eagle’s Medium (Corning, Corning, NY) supplemented
with 10% heat-inactivated fetal bovine serum (Invitro-
gen, Life Technologies, Grand Island, NY) and 1%
penicillin/streptomycin; cells were selected using 5 g/ml
puromycin (VWR, Radnor, PA) and 200 g/ml G418
(VWR, Radnor, PA). ATF expression was induced by treat-
ment with media containing 1g/ml doxycycline (VWR,
Radnor, PA) at 0 h, doxycycline media was refreshed at 48
h, and cells were harvested at 72 h. ATF expression was con-
firmed by hemagglutinin (HA) tag western blot prior to HA
ChIP-seq, histone ChIP-seq and RNA-seq analysis.
ChIP-seq
For HA-tag ChIP-seq, stable MCF7 cell lines were induced
using 100 ng/ml doxycycline (Sigma) at 0 h, doxycycline
media was refreshed at 48 h, and cells were harvested at 72 h
by crosslinking in a final concentration of 1% formaldehyde.
Crosslinking was stopped after 5 min by adding glycine to
a final concentration of 125 mM. Crosslinked cells were
washed in cold phosphate buffered saline, lysed using 1 ml
low-salt IP buffer (150 mM NaCl, 50 mM Tris-HCl (pH7.5),
5 mM EDTA, NP-40 (0.5%), Triton X-100 (1%) contain-
ing protease inhibitors) and aliquoted at 1 × 10∧7 cells/ml.
Cells are then sonicated to a fragment size range of 500–800
bp. Samples were then diluted in 1 ml low-salt buffer and
incubated with 3 l of anti-HA antibody (Covance, Prince-
ton, NJ). Three-hundred microliter Sepharose A beads (GE
Healthcare Life Science) were used for pull-down. Samples
were sequenced at the UNC-CH Genome Analysis Facil-
ity (Chapel Hill, NC) on an HiSeq (Illumina, San Diego,
CA) to read counts of 4.1–67.3 M total reads. For histone
ChIP-seq, antibodies to H3K4me3 (Cell Signaling Tech-
nologies CST9751), H3K9Ac (Cell Signaling Technologies
CST9649) and H3K9me3 (Diagenode pAb-056-050) were
used; samples were prepared as previously described (32).
ChIP-seq analysis
Each sequenced HA ChIP-seq biological replicate for
HA-598 (two replicates), HA-598-SKD (three replicates),
HA-552 (two replicates), HA-552-SKD (three replicates)
and pT3-empty-vector (two replicates) yielded standard
fastq file outputs. Fastq files were mapped to human
genome version GRCh37/hg19 using Bowtie 2.0.1 (33)
with default parameters to produce SAM files. SAM files
were converted to BAM files using SAMTools (34). BAM
files were converted to BED files using BEDTools (35). In
order to call ChIP-seq peaks, BED files were submitted
individually (each with a similarly mapped MCF7 input
BED file as a background reference) to the Sole-Search
Tool (36) with the following parameters: permutation num-
ber, 5; average chromatin fragment size, 150; alpha value,
0.001; peak merge distance, 0; histone blur, no. Resulting
GFF format peak files were sorted by peak height and
truncated to the number of peaks in the smallest replicate
for each set. The top 40% of peaks for each truncated
replicate were tested for statistically significant overlap
versus corresponding replicate total peak files using the
Sole-Search GFF-overlap Tool. All 40% replicate peak
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files satisfied the ENCODE standard of 80% overlap with
truncated corresponding replicates (https://genome.ucsc.
edu/ENCODE/protocols/dataStandards/2010-05-30 mod-
ENCODE TF Chrom Data Standards.pdf). Correspond-
ing replicates were then submitted simultaneously as
merged sets to the Sole-Search Tool for peak calling,
producing sets of merged GFF peak files and SGR visu-
alization files. Again using the Sole-Search GFF-overlap
Tool, peaks for each ATF variation that overlapped with
pT3-empty-vector GFF files or with regions of aneuploidy
in MCF-7 cells were removed to eliminate possible artifacts
not resulting from ATF binding. Remaining ATF peak sets
were sorted by peak height and plotted against peak rank to
select high-confidence (HC) peaks (Supplementary Figures
S1A and B), along with visual inspection of SGR format
visualization files. The Homer genomic suite of tools (37)
was used for tag density plots (annotatePeaks.pl), scatter
plots (annotatePeaks.pl), overlap analysis (mergePeaks),
genomic locations (annotatePeaks.pl) and de novo motif
finding (findMotifsGenome.pl). De novo motif finding
for the top 4000 peaks from each HC ATF peak set was
performed using all hg19 RefSeq gene promoters as a
background for statistical comparison and all nucleotides
within the peaks, as called by the Sole-Search tool, were
subjected to the analysis. The resulting predominant motif
position weight matrix files for each ATF were used to
search for the presence of significant motif matches among
the top 2500 HC peaks for each ATF. The predominant
motif position weight matrix files were restricted to single
nucleotide tolerances to represent partial target sequences
in order to search the entire genome for instances of partial
target sites using annotatePeaks.pl. Histone ChIP-seq
enrichment values for all RefSeq promoter regions (TSS
± 1 kb) were calculated from the average tags per bp
using annotatePeaks.pl within each promoter region. Tag
density plots for histone enrichment at different promoter
categories (downregulated, unchanged, upregulated and
unbound) were calculated using the -hist 200 option of
annotatePeaks.pl. H3K4me3 plots and enrichments before
and after induction were compared to ENCODE datasets
for H3K4me3 in MCF7 (wgEncodeEH000967) to ensure
that uninduced profiles are representative of MCF7 cells.
Whole genome bisulfite sequencing
MCF7:598-SKD cells were either not induced or induced
with doxycycline as described above. Two microgram of ge-
nomic DNA was isolated using a QIAeasy DNA mini kit
(Qiagen, Venlo, The Netherlands) and sonicated using a
Covaris to an average molecular weight of 150 bp. Achieve-
ment of the desired size range was verified by Bioanalyzer
(Agilent) analysis. Fragmented DNA was repaired to gener-
ate blunt ends using the END-It kit (Epicentre Biotechnolo-
gies, Madison, WI) according to manufacturer’s instruc-
tions. Following incubation, the treated DNA was purified
using AmpureX beads from Agencourt. In general, mag-
netic beads were employed for all nucleic acid purifications
in the following protocol. Following end repair, A-tailing
was performed using the NEB dA-tailing module accord-
ing to manufacturer’s instructions (New England Biolabs,
Ipswich, MA). Adapters with a 3′ ‘T’ overhang were then
ligated to the end-modified DNA. For whole genome bisul-
fite sequencing, modified Illumina paired-end (PE) adapters
were used in which cytosine bases in the adapter are re-
placed with 5-methylcytosine bases. Depending on the spe-
cific application, we utilized either Early Access Methyla-
tion Adapter Oligos that do not contain barcodes, or the
adapters present in later versions of the Illumina DNA
Sample Preparation kits, which contain both indices and
methylated cytosines. Ligation was carried out using ultra-
pure, rapid T4 ligase (Enzymatics, Beverly, MA) according
to manufacturer’s instructions. The final product was then
purified with magnetic beads to yield an adapter-ligation
mix. Prior to bisulfite conversion, bacteriophage lambda
DNA that had been through the same library prepara-
tion protocol described above to generate adapter-ligation
mixes was combined with the genomic sample adapter lig-
ation mix at 0.5% w/w. Adapter-ligation mixes were then
bisulfite converted using the Zymo DNA Methylation Gold
kit (Zymo Research, Orange, CA) according to the man-
ufacturer’s recommendations. Final modified product was
purified by magnetic beads and eluted in a final volume
of 20 l. Amplification of one-half the adapter-ligated li-
brary was performed using Kapa HiFi-U Ready Mix for
the following protocol: 98◦ 2′; then six cycles of 98◦ 30′′,
65◦ 15′′, 72◦ 60′′; with a final 72◦ 10′ extension, in a 50
l total volume reaction. The final library product was ex-
amined on the Agilent Bioanalyzer, then quantified using
the Kapa Biosystems Library Quantification kit according
to manufacturer’s instructions. Optimal concentrations to
get the right cluster density were determined empirically
but tended to be higher than for non-bisulfite libraries. Li-
braries were plated using the Illumina cBot and run on the
Hi-Seq 2000 according to manufacturer’s instructions using
HSCS v 1.5.15.1. Image analysis and basecalling were car-
ried out using RTA 1.13.48.0; deconvolution and fastq file
generation were carried out using CASAVA v1.7.1a5. Raw
reads were mapped with [programs/parameters], and per-
cent methyl-C/C was calculated for every CpG dinucleotide
in the human genome. All CpG dinucleotides with a mini-
mum sequencing coverage of 3× were used for downstream
analyses. To determine the average DNA methylation sur-
rounding a region of interest, the annotatePeaks tool of the
HOMER suite was used with the ‘-ratio’ option and a bin
size of 200 bp.
RNA-seq
MCF7 cell lines were grown as described above. Each ex-
periment (no induction control and doxycycline induction)
was performed in triplicate. RNA was harvested using
the Qiagen RNeasy kit and Illumina libraries were made
with the Illumina TruSeq Stranded mRNA Sample Prep
kit according to the manufacturer’s instructions. DNA li-
braries were sequenced on an Illumina HiSeq1500 with read
lengths of 96 bp and read counts of 26–57 million. Pre-
alignment QA/QC and base trimming were performed in
Partek Flow v3.0.14.0321 using fastqc and quality trim.
Reads were mapped to the Gencode version 19 of the hu-
man hg19 reference genome using Tophat (38). Quantifi-
cation to the transcriptome was performed by Partek ex-
pectation maximization (EM). The Partek Flow software
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suite was made available through the USC Norris Medical
Library Bioinformatics Services (http://norris.usc.libguides.
com/nml-bioinfo). Genes with a false discovery rate less
than 0.05 and a change in expression greater than 2-fold
were counted as differentially expressed.
Data access
The MCF7 DHS data (UCSC accession #wgEn-
codeEH000502) and H3K27ac MCF7 (UCSC accession #
wgEncodeEH002872) are from the ENCODE Consortium
(39–42) and are available at http://genome.ucsc.edu; all
ENCODE data used in this study are past the 9 month
moratorium. The other ChIP-seq data, the DNA methyla-
tion data, and the RNA-seq data have been submitted to
GEO (GSE59980).
RESULTS
Six-finger ATFs display widespread binding to the human
genome
For our studies, we used MCF7 cell lines stably express-
ing four different six-finger ATFs under the control of
a doxycycline-inducible promoter (27). Each ATF should
specifically recognize a unique 18 nt region of the human
SOX2 promoter located 552 or 598 bp upstream of the tran-
scription start site (TSS) (Figure 1A). Due to the nature of
the ZNF code (15,43–44), ATFs based on ZNF domains
recognize GC-rich motifs. The ATFs either lack or con-
tain an SKD, a transcriptional repression domain that has
been shown to recruit the KAP1/SETDB1 histone methyl-
transferase which trimethylates histone H3 on lysine 9 (19).
Each ATF also contains a HA-tag, which serves as an anti-
body recognition domain for chromatin immunoprecipita-
tion (ChIP) assays. Previous studies had used ChIP-PCR
to demonstrate that 552-SKD and 598-SKD can bind to
the SOX2 promoter (26,27). However, the previous ChIP-
PCR was limited to specific genomic regions and the overall
specificity of binding was not examined for the ATFs.
Therefore, we performed multiple, independent ChIP-seq
assays for each of the four ATFs (552, 552-SKD, 598 and
598-SKD) using an antibody that recognizes the HA-tag.
As a control, a fifth MCF7 line with stable integration of
the empty ATF vector was also induced with doxycycline
(Dox) and used for background peak subtraction. As ex-
pected, each of the ATFs bound to the correct site within the
SOX2 promoter (Figure 1B). However, binding was not re-
stricted to this promoter region. In fact, thousands of bind-
ing sites were detected for the 552 and 598 ATFs, and the
addition of the SKD effector domain increased the number
of sites for each ATF by about 5-fold (Figure 1C). Although
the peak at the SOX2 promoter was among the top of the
ranked peaks (e.g. having a rank of 258 out of the 25 000
598-SKD peaks), there were thousands of sites of similar
height. The ChIP-seq peak sets for the four ATFs, including
the new effector-specific sites, were robust and reproducible
(Supplementary Figures S1 and S2). Conservative, HC peak
sets for each ATF (cutoffs indicated by the colored circles in
Figure 1C) were chosen for further analysis. A comparison
of the 552 versus 552-SKD and 598 versus 598-SKD sites
revealed that ∼90% of the sites bound by the effector-free
ATFs were also bound by the SKD-containing ATFs (Fig-
ure 1D), again showing the reproducibility of the ChIP-seq
signals.
All ATF variants bind partial target sequences
As noted above, the 18 nt target sites were expected to
be uniquely bound in the human genome. Comparison of
these sequences to the hg19 reference genome revealed that
552 occurs only at chr3:181429514–181429714 and 598 oc-
curs at chr3:181429469–181429669 and chr11:82443421–
82443621. However, we identified thousands of binding
sites for each ATF. We note that both 552-SKD and 598-
SKD have more sites than either of the effector-free parental
ZNFs. We realize that it is difficult to know whether the
thousands of extra sites bound by the 552-SKD and 598-
SKD proteins are a result of differences in the expression
level and/or DNA binding ability of the ZNFs that con-
tain or lack an effector domain. We reasoned that if all
the ‘extra’ peaks in the ZNF-SKD constructs were due to
higher expression levels allowing occupancy of thousands
of additional low affinity sites, perhaps the SKD-unique
peaks would be smaller than those peaks also bound by the
effector-free ZNFs (i.e. the common peaks). However, this is
not the case; ∼3000 of both the 552-SKD unique peaks and
598-SKD unique peaks are equivalent to or higher than the
median peak height from the 5138 common peaks. There-
fore, it is possible that at least some of the ZNF-SKD peaks
could bind to sites other than the SOX2 target site by re-
cruitment to the genome via protein–protein interactions
of the SKD domain with complexes containing other site-
specific DNA binding proteins. As noted above, the SKD
domain is a potent KRAB domain taken from the KRAB-
ZNF transcription factor KOX1 (45). A well-characterized
function of the KRAB domains from KRAB-ZNF pro-
teins is to interact with KAP1. Although there are many
potential KRAB-ZNFs that might interact with KAP1, in
fact, only one (ZNF274) has been identified to co-localize
with KAP1 on the genome (19–20,46). The most robust
ZNF274/KAP1 recruitment sites are at the 3′ exons of ZNF
genes on chromosome 19. Interestingly, KAP1 functions as
a trimer and therefore could possibly interact with ZNF274
and with the ZNF-SKD proteins simultaneously. If so, then
perhaps the KAP1 protein was interacting with both the
ATF-SKD and ZNF274, with the DNA-binding proper-
ties of ZNF274 bringing the ATF-SKD to genomic re-
gions lacking the 598 or 552 motifs. Therefore, we examined
whether the ZNF-SKD proteins can be found at the normal
KAP1 binding locations by comparing the binding patterns
of SKD-552, SKD-598 and ZNF274. ZNF274 ChIP-seq
has not been performed on MCF7 cells. However, ZN274
sites vary minimally across all analyzed cell lines. Therefore,
we used a pan-ZNF274 site dataset, encompassing all repro-
ducible ZNF274 binding sites from 11 different normal and
cancer cell lines. We found that only three out of 25 000 552-
SKD peaks and two out of 25 000 598-SKD peaks overlap
with ZNF274 binding sites at ZNF 3′ exons (Supplemen-
tary Figure S3). Therefore, the large number of observed
effector-specific sites were not due to co-localization with
the ZNF274/KAP1 complex. However, this does not elimi-
nate the possibility that the ATF-SKDs are being recruited
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Figure 1. ChIP-seq analysis of ATFs directed to the SOX2 promoter. (A) Tandem arrays of six zinc finger DNA binding domains were engineered to bind
to two different sites, 598 or 552 bp upstream of the transcription start site of the SOX2 gene. Each zinc finger array carries a carboxy-terminal HA-tag
and lacks or contains an amino-terminal SKD repression domain. (B) ChIP-seq peaks for the four ATFs at the SOX2 gene are shown; the position of the
SOX2 gene is indicated below the tracks and the peak height (number of sequenced tags) is indicated on the Y-axis. (C) ChIP-seq inflection curves for the
four ATFs are shown; peak height is shown on the Y-axis and peak rank is shown on the X-axis. The approximate position of the peak at the target site in
the SOX2 promoter is indicated by a black arrow for each ATF. For example, the SOX2 peak was ranked 275 out of the entire >45 000 sites in the 598-SKD
peak set. High-confidence peak cutoffs are indicated by colored circles along the curves. (D) Venn diagrams comparing the high-confidence peak sets for
the no-effector versus SKD domain-containing 552 and 598 ATFs.
by KAP1 in complex with other (to date uncharacterized)
cellular KRAB-ZNFs to sites that are mutually exclusive
from ZNF274-KAP1 genomic sites.
Another possibility for promiscuous binding is that the
ATFs are using only a subset of their six fingers to con-
tact the genomic DNA. To address this possibility, we per-
formed de novo motif analysis of the top 4000 peaks for
each ATF, identifying a predominant motif for each peak
set (Figure 2A). Clearly, the 552- and 598-based ATFs fre-
quently bound to sequences resembling a subset of the 18
nt in the target sequences and the addition of the SKD do-
main did not greatly affect the predominant motif for either
552 or 598. A majority of the top ranked sites for each ATF
contain the identified predominant submotif; no other sig-
nificant motifs were detected, even in the sites that lacked
a strong match to the predominant motif (Supplementary
Figure S4). The percentages of total binding sites corre-
sponding to the partial motifs are 59%, 50%, 39% and 30%
for 598, 552, 598-SKD and 552-SKD, respectively. Effector-
free ATF peak height correlated more strongly with par-
tial motif presence, suggesting greater dependence on the
partial motif for binding than the ATF-SKDs. Compari-
son to the target sequence suggests that the 552 ATFs were
mainly utilizing fingers 2–5 and the 598 ATFs were mainly
utilizing fingers 3–6. Unlike the high specificity of the 18
nt motifs to which the ATFs were designed to bind, these
12 nt partial target subsequences occur respectively 1171
and 6532 times in the genome (Figure 2B). A small num-
ber of these 12-mers are found in regions of open chro-
matin, identified as a DNAse I hypersensitive site (DHS).
Of these, between 40–70% are bound by an ATF. However,
the vast majority of the 12-mer motifs are found in a non-
DHS, which are usually inaccessible to most transcription
factors. In fact, an analysis of 69 TFs in six cell lines by the
ENCODE Consortium indicated that over 98% of all tran-
scription factor ChIP-seq peaks fall within a DHS (47,48).
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Figure 2. The ATFs bind to partial target sequence motifs. (A) Motif density plots of the percentage of the top 2500 peaks that contain the predominant
motif (as determined by de novo motif analysis) for each ATF. 598 and 552 design target sequences are shown, compared to the predominant motifs
identified by de novo motif analysis of the top 4000 peaks for each ATF. (B) Analysis of ATF binding to the 598 and 552 partial target sequences found
throughout the genome, divided into regions of open chromatin (DHS) or other regions not overlapping open chromatin.
Surprisingly, 21% of all possible 12-mer partial 552 target
sequences in the genome and 27% of all partial 12-mer 598
target sequences in the genome found in non-DHS regions
are bound by at least one form of the corresponding ATF.
For the case of 598-SKD, more than 1700 binding sites cor-
responded to regions that contained the 12-mer but were
not identified as a DHS.
ATF binding in relation to genomic and epigenomic structure
Our analyses which revealed that some of the bound 12-
mer motif-containing sites are not within a DHS suggested
that the ATFs have the ability to bind to nucleosome-free
(characterized by DHS) and nucleosome-containing sites.
To further characterize all binding sites of the ATFs, we de-
termined their genomic locations relative to promoter re-
gions, enhancer regions and DHS (Figure 3A). The major-
ity of the binding sites for 552 and 598 were in promoter
regions (as defined by ± 1000 nt from a TSS); we note that
the binding site at the SOX2 promoter was ranked 55 out of
the 5917 promoters bound by 598-SKD. Because the major-
ity of the promoters in the human genome are GC-rich, we
thought that perhaps the large number of promoter peaks
in the ChIP-seq data (ranging from ∼2500 in 552 to ∼8000
in 552-SKD) was due to the presence of multiple 12-mer
binding sites and therefore multiple peaks in a given pro-
moter region. However, as shown in Figure 3B, the num-
ber of uniquely identified promoters was similar to the total
number of promoters identified for each ATF. This suggests
that the ATFs have the potential to regulate up to 8000 pro-
moters in MCF7 cells.
Interestingly, although the number of total binding sites
increased ∼5-fold when the effector domain was added,
most of the newly acquired sites were not in promoter re-
gions. Furthermore, promoter peaks were distributed some-
what evenly among peaks, with little correlation to peak
rank (Supplementary Figure S5), suggesting that many ro-
bust binding sites were outside of promoters. TFs can bind
to both promoters and enhancers and we therefore hypothe-
sized that the new sites were located at enhancer regions. Us-
ing H3K27Ac ChIP-seq data from the ENCODE project,
we compared the location of the binding sites for the four
ATFs to active enhancers in MCF7 cells (49). However, very
few of the ATF binding sites were in active enhancer re-
gions. As noted above, most transcription factor binding
sites fall within a DHS (47,48). DHS regions encompass
not only promoters and active enhancers, but also include
a large set of regions of open chromatin that are available
for transcription factor binding but the transcription fac-
tors that are bound are not sufficient to recruit activating
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Figure 3. Addition of the SKD domain results in more distal binding sites for both ATFs. (A) For each of the four ATFs, the percentage of binding sites
located in promoters, enhancers (H3K27ac-enriched regions) and other regions of open chromatin not corresponding to promoters or enhancers (denoted
as ‘other DHS’), and non-DHS regions. (B) Location analysis for all four ATF variants displaying the number of uniquely bound genetic elements; the
average number of peaks per unique element is shown.
histone acetylation complexes (thus, the sites are not clas-
sified as active enhancers). We expected that most of the
ATF binding sites that are not in promoters or active en-
hancers would fall within the category of non-promoter,
non-enhancer DHS (which we denote as ‘other DHS’ re-
gions). However, we found that very few of the ATF peaks
were within this category. In fact, the largest set of non-
promoter peaks for each ATF lies outside of DHS (de-
noted “non-DHS’ regions). The surprising finding that the
ATFs could bind to non-DHS regions suggested that per-
haps these ATFs could bind within regions of methylated
DNA (since most of the genome is methylated). Indeed,
we found that many of the peaks are within heavily methy-
lated regions, with 552-SKD and 598-SKD non-DHS peaks
binding almost exclusively in methylated regions (Figure
4A). It is possible that these methylated regions are not as
heavily condensed as regions considered to be heterochro-
matin (e.g. silenced promoters) and thus the ATFs can ac-
cess their motifs. We also stress that we have not yet shown
that a specific CpG in the genomic sequence directly con-
tacted by the factors is methylated. A browser snapshot ex-
ample of a promoter peak and an ‘other’ peak is shown in
Figure 4B and C; the promoter peak has low DNA methyla-
tion and high H3K4me3 whereas the ‘other’ peak has high
DNA methylation and no H3K4me3 mark.
598-SKD affects activity of only a subset of bound promoters
To determine the functional consequences of binding of an
ATF having a domain that recruits a repressive histone-
modifying complex to thousands of promoters, we per-
formed ChIP-seq for histone modifications before and af-
ter induction of 598-SKD. We found that, in general, the
level of H3K4me3 did not significantly change upon bind-
ing by 598-SKD when all 5915 bound promoters are consid-
ered together (Figure 5). These ChIP-seq analyses suggested
that the recruitment of 598-SKD was not causing changes
in gene expression at most of the bound promoters. To test
this hypothesis, we performed RNA-seq analysis before and
after induction of the 598-SKD ATF. As shown in Figure
6A, 769 genes were upregulated and 1066 were downreg-
ulated upon induction of 598-SKD. To separate primary,
direct effects from secondary, downstream effects on gene
regulation, we selected for further analysis only those genes
whose promoters were in the set of 5915 promoters bound
by 598-SKD (Figure 6B). In this subset of genes, we found
that only ∼10% of the bound promoters showed changes in
gene expression (416 were downregulated and 264 were up-
regulated). Representative 598-SKD promoter binding sites
and histone modification profiles for a downregulated gene
and an upregulated gene are shown in Figure 6C and D, re-
spectively.
As noted above, in general, the set of ∼6000 promoters
bound by 598-ATF did not show differences in H3K4me3
patterns. However, it was possible that promoters of genes
having expression changes would show differences in his-
tone marks. Therefore, we compared histone modifications
at the set of all bound promoters, bound and downregu-
lated promoters, bound and upregulated promoters and all
unbound promoters. While H3K4me3 and H3K9ac levels
show slight overall decreases genome-wide, we found es-
sentially no differences in histone marks at any subset of
bound promoters as compared to unbound promoters (Fig-
ure 7). CpG density and peak width at bound promoters
also showed no correlation with the ability to downregu-
late gene expression (Supplementary Figure S6). However,
we did find that there was a higher motif density in the set
of repressed peaks than in the other two sets (Figure 8A)
and that the overall peak height was higher for both 598-
SKD and 598 for the set of bound and repressed promoters
(Figure 8B). Because 598-SKD could possibly downregu-
late genes by blocking elongating RNA Polymerase II, we
compared the position of the 598-SKD peaks relative to the
TSS and expression changes at those genes (Figure 8C). We
found that 598-SKD binding was only enriched at the most
5′ end of gene bodies (10–15% of the length of the gene),
suggesting that effects on expression are largely dictated by
interactions at gene promoters.
DISCUSSION
ATFs and genomic nucleases based on a DNA binding
platform consisting of multiple ZNF domains are cur-
rently being developed for clinical applications. However,
no genome-wide investigations into their binding specificity
have been performed. We have created six-finger ATFs that
should each specifically recognize a different 18 nt region
of the human SOX2 promoter; each ATF is constructed
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Figure 4. The ATFs can bind to regions of methylated DNA. (A) DNA methylation tag density plots for the four categories of ATF binding sites, displaying
the average genomic methylation ± 4 kb from peak centers of each ATF variant. Genome browser pile-up tracks for a representative, robust promoter
peak (B) and (C) a ‘non-DHS’ peak. Histone tracks for each display DNA methylation coverage and levels and H3K4me3 peaks from MCF7 cells.
Figure 5. Binding of 598-SKD does not affect H3K4me3 levels at pro-
moters. ChIP-seq scatter plot for normalized H3K4me3 tags at 598-SKD-
bound promoters (TSS ± 1 kb) at 0 days and 3 days of 598-SKD induction.
The dashed line is x = y, the solid line is the best-fit slope of the plotted
data (with slope equation), and the SOX2 promoter is represented as a
black circle.
such that it contains or lacks an SKD domain that interacts
with a transcription repression complex. ChIP-seq analy-
sis of the effector-free ATFs in MCF7 breast cancer cells
identified thousands of binding sites, mostly in promoter re-
gions; the addition of an SKD domain increased the num-
ber of binding sites ∼5-fold, with a majority of the new sites
located outside of promoters. De novo motif analyses sug-
gest that the lack of binding specificity is due to subsets
of the finger domains being used for genomic interactions.
Although the ATFs display widespread binding, few genes
showed expression differences; genes repressed by the ATF-
SKD have stronger binding sites and are more enriched for
a 12 nt partial target motif. Interestingly, epigenetic analy-
ses indicate that the transcriptional downregulation caused
by the ATF-SKD is not due to loss of H3K4me3 on the re-
pressed promoters.
Potential off-target effects due to 598-SKD binding to 25
000 genomic sites are somewhat muted by the observation
that the majority of these sites are not at promoter or en-
hancer regions, suggesting that the majority of the off-target
binding would not affect gene expression. However, we did
identify ∼6000 promoters that were bound by 598-SKD. At
first glance, this may suggest that off-target binding would
be a serious problem in that thousands of genes would show
differences in expression. To the contrary, we found that
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Figure 6. 598-SKD affects activity of only a subset of bound promoters. (A) A volcano plot of genome-wide expression changes and upon 3 day induction
of 598-SKD. Significantly downregulated genes and upregulated genes (≥2-fold, P < 0.05) and counts are shown in green and red, respectively. SOX2 is
represented as a black circle. (B) Scatter plot for all significant (P < 0.05) expression changes at genes with promoters bound by 598-SKD, comparing 0
days and 3 days of 598-SKD induction. Significantly downregulated and upregulated genes (P < 0.05 and expression changed ≥2-fold) with counts are
shown in green and red, respectively. SOX2 is represented as a black circle. Expression changes that were <2-fold, but with P > 0.05, are shown in gray.
(C) Genome browser pile-up tracks for a high-confidence 598-SKD peak at a representative downregulated gene promoter and (D) an upregulated gene
promoter. Histone tracks for each display H3K4me3 at 0 days and 3 days of 598-SKD induction.
Figure 7. Changes in gene expression are not correlated with changes in histone marks. Tag density plots for K4me3, K9ac and K9me3 modifications
of histone H3 at 598-SKD-bound promoters, bound and downregulated promoters, bound and unchanged promoters, bound and upregulated promoters
and unbound promoters at 0 and 3 days of 598-SKD induction.
less than 700 genes whose promoters were bound by 598-
SKD showed expression changes (Figure 9). It is possible
that this subset of genes is just the earliest to respond and
that continued 598-SKD induction would eventually drive
more widespread downregulation. Nevertheless, our results
suggest that off-target binding is perhaps less of an issue
than is lack of function upon binding.
The SKD domain is an optimized KAP1-interaction do-
main from the KRAB-ZNF Kox1 (45). KAP1 is a large
protein that serves as a scaffold for components of a com-
plex that is thought to be involved in heterochromatin for-
mation (50). Components of the NuRD histone deacety-
lase complex and the H3 lysine 9-specific histone methyl-
transferase SETDB1 bind to KAP1 (51) and are thought
to work cooperatively to form condensed heterochromatin.
We have previously used ChIP-seq to perform a genome-
wide functional analysis of KAP1, identifying thousands
of promoter regions and intragenic regions to which KAP1
is recruited (20). However, although the identified binding
sites are quite strong and found in multiple cell types, KAP1
did not appear to regulate the expression of most genes that
are near its binding sites (20). We note that KAP1 fused to
DNA binding domains has been effectively used to regulate
artificial promoter constructs containing multiple binding
sites for the fusion protein (52–56). Work with other ATFs
has also shown increased activity when multiple copies of
the ATF are brought to a single promoter (57,58). Taken
together, such studies suggest that perhaps an ATF-SKD
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Figure 8. Analysis of activated versus repressed promoters. (A) Tag density plot for the frequency of the predominant 598-SKD-bound motif (shown
above the plot, representing a partial design target motif) at bound promoters. Colored plot lines correspond to 598-SKD-bound promoters at genes
with unchanged, downregulated or upregulated activity. (B) Tag density plots for 598-SKD and 598 ChIP-seq tags at 598-SKD target promoters across
expression groups; plot colors correspond to those in (A). (C) Tag density plots for 598-SKD across promoters and gene bodies; plot colors correspond to
those in (A).
acquires the ability to act as a transcriptional repressor only
under certain conditions, such as if multiple complexes are
recruited via high-affinity DNA binding proteins and are
properly positioned near a TSS.
We did find that the promoters that were repressed by
598-SKD had a higher enrichment of motifs. Such studies
suggest that one option might be to target a given promoter
with multiple ATFs that recognize binding sites spaced ap-
propriately apart to allow simultaneous binding. Although
many thousands of off-target binding events for each of the
ATFs may occur, perhaps the only promoters that would be
highly regulated would be those that have the sites for all of
the ATFs. One recent study targeted over 300 different sites
across five gene promoters (OCT4, SOX2, KLF4, c-MYC
and miR302/367) using five- or six-fingered artificial ZNFs
with p65, VP16 and VP64 activation domains (59). They
found that different effector domains were better suited to
upregulate each gene and that not all sites resulted in signif-
icant target gene expression changes. Genome-wide binding
analyses were not performed and therefore off-target bind-
ing was not investigated.
We note that some genes driven by promoters that were
bound by 598-SKD showed increased RNA levels. Al-
though it is certainly possible that many of these changes
are indirect responses to upstream effects on signaling path-
ways, KAP1 has been previously associated with transcrip-
tional activation. For example, using reporter-promoter as-
says, KAP1 was shown to function as a co-activator for
NGFI-B and CCAAT-enhancer-binding protein (60–62).
Also, the effective re-activation of the endogenous Oct4
promoter by a six ZNF ATF required a KRAB domain
(63). The degree of activation varied in different cell types,
in accordance with previous studies that have suggested
that KAP1 function is cell type-specific (50). Thus, al-
though KRAB domain-containing ATFs are traditionally
described as transcriptional repressors, they might also
function as activators; the mechanisms by which KAP1 can
activate transcription are not known.
In conclusion, although we were initially dismayed by
the identification of thousands of off-target binding sites,
such a large number of binding events have provided us
with the opportunity to gain insight into several features
of ATF-mediated gene regulation. For example, it was ex-
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Figure 9. Widespread binding but limited regulation. Overall starting
numbers for 598-SKD peaks (25 000) and RefSeq hg19 promoters (45 069)
converge on 416 genes as each set is filtered for 598-SKD binding, the num-
ber of unique promoters bound, and gene downregulation.
citing to observe binding of the ATFs to regions of highly
methylated DNA, suggesting that they may be useful as pi-
oneering factors to target (and subsequently activate) a si-
lenced promoter. Few characterized transcription factors
have this ability (in fact, ZNF274 is the only factor studied
by ENCODE that shows binding outside of a DHS) and
thus ATFs based on ZNFs may provide a unique opportu-
nity to remodel heterochromatic genomic regions. Also, our
studies suggest that the outside fingers do not always con-
tribute to binding specificity; perhaps constructing eight-
finger ATFs would allow the internal six fingers to con-
tribute to binding specificity and would result in fewer off-
target sites. Finally, the fact that only a small percentage
of promoters bound by 598-SKD showed gene expression
changes, that bound promoters could be either repressed or
activated, and the fact that previous studies have suggested
that KAP1-mediated regulation is cell type-specific, we sug-
gest that before use in clinical settings, preliminary studies
in cell culture should be performed to test whether an ATF-
SKD, or more likely a combination of ATF-SKDs, will acti-
vate or repress your gene of interest. We also are aware that
other genome targeting platforms, such as clustered reg-
ularly interspaced short palindromic repeats (CRISPRs),
may provide more specificity (31,64–66). In fact, after learn-
ing of our studies, others have directly compared the bind-
ing specificity of a CRISPR and a ZNF targeted to the same
genomic region; the ZNFs had many more off-target bind-
ing sites (O’Geen and Segal, personal communication).
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